ALSUntangled #71: Nuedexta

Sun, Yan; Benatar, Michael; Cadavid, Javier Mascias; Ennist, Dave; Wicks, Paul; Staats, Kim A.; Beauchamp, Morgan; Jhooty, Sartaj; Pattee, Gary L.; Brown, Andrew; Bertorini, Tulio E.; Barkhaus, Paul E.; Bromberg, Mark B.; Bedlack, Richard; Li, Xiaoyan

doi:10.1080/21678421.2023.2239292

Cited by 3 publications

(3 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Dextromethorphan is an NMDA receptor antagonist that is commonly used as a cough suppressant along with being able to treat PBA [51] . PBA manifests as recurrent, involuntary, and sometimes abrupt bouts of crying or laughing, often disproportionate to the individual's emotional state [9] . Quinidine is a class 1a antiarrhythmic drug that is commonly used to block cardiac sodium channels to prolong action potential duration through QT prolongation and QRS segments [52] .…”

Section: Nuedextamentioning

confidence: 99%

See 1 more Smart Citation

Assessing the efficacy of amyotrophic lateral sclerosis drugs in slowing disease progression: A literature review

Ansari,

Alam,

Nadora

et al. 2024

AIMSN

View full text Add to dashboard Cite

<abstract> <p>Amyotrophic lateral sclerosis (ALS) is a fatal and intricate neurodegenerative disease that impacts upper and lower motor neurons within the central nervous system, leading to their progressive destruction. Despite extensive research, the pathogenesis of this multifaceted disease remains elusive. The United States Food and Drug Administration (FDA) has granted approval for seven medications designed to address ALS and mitigate its associated symptoms. These FDA-sanctioned treatments are Qalsody, Relyvrio, Radicava, Rilutek, Tiglutik, Exservan, and Nuedexta. In this review, the effects of these seven drugs on ALS based on their mechanism of action, dosing, and clinical presentations are comprehensively summarized. Each medication offers a distinct approach to manage ALS, aiming to alleviate the burdensome symptoms and slow the disease's progression, thereby improving the quality of life for individuals affected by this neurological condition. However, despite these advancements in pharmaceutical interventions, finding a definitive cure for ALS remains a significant challenge. Continuous investigation into ALS pathophysiology and therapeutic avenues remains imperative, necessitating further research collaborations and innovative approaches to unravel the complex mechanisms underlying this debilitating condition.</p> </abstract>

show abstract

Section: Nuedextamentioning

confidence: 99%

“…It dissolves upon contact with the tongue to obviate the need for swallowing a pill or liquid [8] . Nuedexta, approved in 2010, is another promising drug that combines dextromethorphan hydrobromide (HBr) and quinidine sulfate to manage pseudobulbar affect (PBA) [9] .…”

Section: Introductionmentioning

confidence: 99%

Assessing the efficacy of amyotrophic lateral sclerosis drugs in slowing disease progression: A literature review

Ansari,

Alam,

Nadora

et al. 2024

AIMSN

View full text Add to dashboard Cite

show abstract

“…The thickened liquid and oral film forms of Riluzole, Tiglutik and Exservan were later developed and approved by the FDA in 2018 and 2019, respectively. Nuedexta, the first FDA-approved drug for pseudobulbar affect, is a combination of quinidine sulfate and dextromethorphan hydrobromide that regulates neurotransmission in the central nervous system and showed positive effects on bulbar functions in ALS patients [ 24 , 25 ]. Radicava, a free-radical scavenger, acts to remove reactive oxygen species and reduce oxidative stress that was shown to be involved in ALS pathogenesis [ 26 ].…”

Section: Introduction To Alsmentioning

confidence: 99%

Updates on Disease Mechanisms and Therapeutics for Amyotrophic Lateral Sclerosis

Nguyen

2024

Cells

View full text Add to dashboard Cite

Amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, is a motor neuron disease. In ALS, upper and lower motor neurons in the brain and spinal cord progressively degenerate during the course of the disease, leading to the loss of the voluntary movement of the arms and legs. Since its first description in 1869 by a French neurologist Jean-Martin Charcot, the scientific discoveries on ALS have increased our understanding of ALS genetics, pathology and mechanisms and provided novel therapeutic strategies. The goal of this review article is to provide a comprehensive summary of the recent findings on ALS mechanisms and related therapeutic strategies to the scientific audience. Several highlighted ALS research topics discussed in this article include the 2023 FDA approved drug for SOD1 ALS, the updated C9orf72 GGGGCC repeat-expansion-related mechanisms and therapeutic targets, TDP-43-mediated cryptic splicing and disease markers and diagnostic and therapeutic options offered by these recent discoveries.

show abstract

Current potential pathogenic mechanisms of copper-zinc superoxide dismutase 1 (SOD1) in amyotrophic lateral sclerosis

Wang,

Chen,

et al. 2024

Reviews in the Neurosciences

View full text Add to dashboard Cite

Amyotrophic lateral sclerosis (ALS) is a rare neurodegenerative disease which damages upper and lower motor neurons (UMN and LMN) innervating the muscles of the trunk, extremities, head, neck and face in cerebrum, brain stem and spinal cord, which results in the progressive weakness, atrophy and fasciculation of muscle innervated by the related UMN and LMN, accompanying with the pathological signs leaded by the cortical spinal lateral tract lesion. The pathogenesis about ALS is not fully understood, and no specific drugs are available to cure and prevent the progression of this disease at present. In this review, we reviewed the structure and associated functions of copper-zinc superoxide dismutase 1 (SOD1), discuss why SOD1 is crucial to the pathogenesis of ALS, and outline the pathogenic mechanisms of SOD1 in ALS that have been identified at recent years, including glutamate-related excitotoxicity, mitochondrial dysfunction, endoplasmic reticulum stress, oxidative stress, axonal transport disruption, prion-like propagation, and the non-cytologic toxicity of glial cells. This review will help us to deeply understand the current progression in this field of SOD1 pathogenic mechanisms in ALS.

show abstract

ALSUntangled #71: Nuedexta

Cited by 3 publications

References 26 publications

Assessing the efficacy of amyotrophic lateral sclerosis drugs in slowing disease progression: A literature review

Assessing the efficacy of amyotrophic lateral sclerosis drugs in slowing disease progression: A literature review

Updates on Disease Mechanisms and Therapeutics for Amyotrophic Lateral Sclerosis

Current potential pathogenic mechanisms of copper-zinc superoxide dismutase 1 (SOD1) in amyotrophic lateral sclerosis

Contact Info

Product

Resources

About